MET and adenocarcinoma: By contrast, the adenocarcinoma cell line H1993 from a metastatic tumor showed a very potent activation of the c-MET pathway, with also a high activation of the HER2 and SHC pathways, and a moderate activation of the HER3 and HER1 pathways.